EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of ABCB1 SNP polymorphisms on the plasma concentrations and clinical outcomes of rivaroxaban in Chinese NVAF patients: a population pharmacokinetic-based study

Fei Wang, Ze Li, Youqi Huang, Qin Liu, Libin Zhao, Honghong Wang, Hongjin Gao, Mingyu Chen, Yuze Lin, Xingang Li, Min Chen

Frontiers in Pharmacology · 29.04.2025 · 16

DOI: 10.3389/fphar.2025.1574949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2025. Verfasst von Fei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Provincial Geriatric Hospital, Clinical College of Fujian Medical University, Fuzhou, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study utilized a population pharmacokinetic (PPK) approach to assess the influence of ABCB1 genetic polymorphisms on the plasma concentrations and clinical outcomes of rivaroxaban.

Methods

The PPK model for rivaroxaban was developed using the nonlinear mixed-effects modelling approach and Monte Carlo simulations were employed to derive peak concentration (C max ) and trough concentration (C trough ). ABCB1 genetic variants were analyzed for their impact on the plasma concentrations and clinical outcomes.

Results

Analysis of 287 rivaroxaban plasma concentrations from 228 non-valvular atrial fibrillation (NVAF) patients revealed significant associations between AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ratios and the apparent clearance (CL/F), the apparent volume of distribution (V/F). ABCB1 1236C>T TT and ABCB1 c.2482-2236C>T CC genotypes exhibited higher dose-adjusted C max (C max /D) compared to other relevant genotypes. Additionally, the ABCB1 3435C>T TT genotype showed lower dose-adjusted C trough (C trough /D) compared to CC or CT genotypes. For clinical outcomes, the ABCB1 c.2482–2236C>T CC genotype had a higher bleeding risk compared to TT (RR = 1.99, 95% CI 1.08–3.69) or CT genotypes (RR = 1.42, 95% CI 1.04–1.92), and ABCB1 3435C>T TT genotype showed a higher thromboembolic risk compared to CC genotype (RR = 3.48, 95% CI 1.02–11.85).

Conclusion

The PPK model incorporated CL/F and V/F with the covariate AST/ALT. Model-based simulations revealed that ABCB1 1236C>T, ABCB1 c.2482–2236C>T, and ABCB1 3435C>T genotypes had significant impacts on the plasma concentrations of rivaroxaban. Specifically, ABCB1 c.2482-2236C>T and ABCB1 3435C>T genotypes were associated with bleeding events and thromboembolic events, respectively.

Schlagwörter

Stichwörter der Autor:innen

ABCB1 genetic polymorphismsTDM (therapeutic drug monitoring)non-valvular atrial fibrillationpopulation pharmacokineticrivaroxaban

Autor:innen und Institutionen

  • Department of Pharmacy, Fujian Provincial Geriatric Hospital, Clinical College of Fujian Medical University, Fuzhou, China.
  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Shengli Clinical College of Fujian Medical University, School of Pharmacy, Fujian Medical University, Fuzhou, China.
  • Department of Intensive Care Unit, Fujian Provincial Geriatric Hospital, Clinical College of Fujian Medical University, Fuzhou, China.
  • Department of Pharmacy, Liuzhou Maternity and Child Healthcare Hospital, Affiliated Maternity Hospital, Liuzhou, China.
  • Department of Pharmacy, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Liuzhou, China.

Zitieren

APA

Wang, F., Li, Z., Huang, Y., Liu, Q., Zhao, L., Wang, H., Gao, H., Chen, M., Lin, Y., Li, X., & Chen, M. (2025). Effect of ABCB1 SNP polymorphisms on the plasma concentrations and clinical outcomes of rivaroxaban in Chinese NVAF patients: a population pharmacokinetic-based study. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1574949

Vancouver

Wang F, Li Z, Huang Y, Liu Q, Zhao L, Wang H, et al. Effect of ABCB1 SNP polymorphisms on the plasma concentrations and clinical outcomes of rivaroxaban in Chinese NVAF patients: a population pharmacokinetic-based study. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1574949

BibTeX
@article{Wang2025,
  author = {Wang, Fei and Li, Ze and Huang, Youqi and Liu, Qin and Zhao, Libin and Wang, Honghong and Gao, Hongjin and Chen, Mingyu and Lin, Yuze and Li, Xingang and Chen, Min},
  title = {Effect of ABCB1 SNP polymorphisms on the plasma concentrations and clinical outcomes of rivaroxaban in Chinese NVAF patients: a population pharmacokinetic-based study},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1574949}
}
Kostenlos starten →